CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice

Advertisement

Nipro April 2026

Driving R&D Towards 2030 – Waging War on Carbon

The largest threat currently faced by humankind is the ever-rising CO2 levels in the air we breathe. In our lifetime, the CO2 level has increased by 33% from 300ppm to 415ppm. The limit for the indoor CO2 level that is without risk to humans is somewhere between 1000 and 2000ppm. Bill Treneman at UPC Cambridge showcases how we have perhaps only 200 years until human health is affected by the CO2 that we breathe in the air, if humans do nothing to change current trends. 

 

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026